Who Paid My Doc
Jeremy Jones
Pain Medicine Lakeway, TX Medical Doctor
NPI 1376839688 CMS profile 1738321
200 Medical Pkwy Ste 210, Ste 210, Lakeway, TX 78738
General payments
$5,449
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Jeremy Jones of Lakeway, TX is reported in the CMS Open Payments database as having received $5,449 across 266 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 75th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $221 | 17 | |
| 2024 | General | $218 | 10 | |
| 2023 | General | $393 | 17 | |
| 2022 | General | $546 | 32 | |
| 2021 | General | $1,655 | 54 | |
| 2020 | General | $940 | 58 | |
| 2019 | General | $1,475 | 78 |
Beside peers
- Jeremy Jones
- Pain Medicine median
- Middle half of Pain Medicine
- National median
In program year 2025, general payments to Jeremy Jones were reported at $221. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.
Show as a table
| Year | Jeremy Jones | Pain Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,475 | $409 | $115–$1,311 | $163 |
| 2020 | $940 | $214 | $66–$666 | $114 |
| 2021 | $1,655 | $299 | $84–$899 | $132 |
| 2022 | $546 | $335 | $103–$1,149 | $149 |
| 2023 | $393 | $376 | $114–$1,228 | $160 |
| 2024 | $218 | $387 | $115–$1,173 | $164 |
| 2025 | $221 | $402 | $130–$1,173 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 18 drugsPart D claims
1,434
Drug cost
$25,124
Branded share of claims
18.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 192 | $5,915 | |
| Gabapentin | Generic | 335 | $3,999 | |
| Pregabalin | Generic | 146 | $3,559 | |
| Celecoxib | Generic | 136 | $2,666 | |
| Tizanidine Hcl | Generic | 153 | $1,907 | |
| Naloxone Hcl | Generic | 24 | $1,637 | |
| Duloxetine Hcl | Generic | 57 | $1,207 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 31 | $930 | |
| Oxycodone Hcl | Generic | 72 | $894 | |
| Tramadol Hcl | Generic | 88 | $606 |
The 10 drugs with the highest cost, of 18 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 64 billing codesPaid by Medicare
$268,088
Medicare patients
412
Services billed
52,956
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Ischemic heart disease | 33% | |
| Depression | 27% | |
| Diabetes | 21% | |
| Chronic kidney disease | 20% | |
| Atrial fibrillation | 18% | |
| Cancer | 17% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 171 | 20,560 | $2,107 |
| Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml Q9965 | Office | 105 | 1,470 | $1,751 |
| Injection, methylprednisolone acetate, 80 mg J1040 | Office | 52 | 62 | $422 |
| Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 | Office | 49 | 1,080 | $323 |
| Injection, bupivicaine, not otherwise specified, 0.5 mg J0665 | Office | 227 | 23,850 | $234 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 39 | 960 | $85 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
266 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pain Medicine in Texas
Related records
Pain Medicine in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Pain Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.